{"id":257,"date":"2024-09-05T07:01:47","date_gmt":"2024-09-05T07:01:47","guid":{"rendered":"https:\/\/www.leapfrog.bio\/?p=257"},"modified":"2026-10-19T12:20:48","modified_gmt":"2026-10-19T19:20:48","slug":"leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform","status":"publish","type":"post","link":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/","title":{"rendered":"Leapfrog Bio annonce la publication dans la revue Nature Precision Oncology de r\u00e9sultats validant sa plateforme exclusive de pharmacog\u00e9nomique de pr\u00e9cision (PGx)"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1352px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><em>Des analyses r\u00e9trospectives de preuve de concept r\u00e9alis\u00e9es \u00e0 partir de m\u00e9dicaments anticanc\u00e9reux d\u00e9j\u00e0 commercialis\u00e9s d\u00e9montrent la pertinence clinique des pr\u00e9dictions de la plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx).<\/em><\/p>\n<p><em><\/em><\/p>\n<p><em><\/p>\n<p>La plateforme exclusive de pharmacog\u00e9nomique de pr\u00e9cision (PGx) permet d\u2019identifier rapidement de nouvelles options th\u00e9rapeutiques pour les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF).<\/p>\n<p><\/em><\/p>\n<p><em><\/em><\/p>\n<p><em>Novel approach utilizes pharmacogenetic in vitro screening of clinical-stage molecules to target major solid tumor markets<\/em><\/p>\n<p><strong>San Mateo (Californie), le 5 septembre 2024<\/strong> \u2014 Leapfrog Bio, une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique qui acc\u00e9l\u00e8re le d\u00e9veloppement de m\u00e9dicaments en oncologie en identifiant de nouvelles th\u00e9rapies pour des mutations oncog\u00e9niques difficiles \u00e0 cibler, a annonc\u00e9 aujourd\u2019hui la publication d\u2019un article dans la revue <a href=\"https:\/\/www.nature.com\/articles\/s41698-024-00673-z\">npj Precision Oncology (Nature Portfolio)<\/a> d\u00e9crivant et validant sa plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx). Cette approche novatrice permet de cribler et d\u2019identifier des combinaisons m\u00e9dicament\u2013g\u00e9notype cliniquement exploitables, susceptibles d\u2019avoir un impact significatif sur la survie globale des patients atteints de cancer.\n\nLa plateforme \u00e9value des cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF) et s\u2019appuie sur la biologie r\u00e9elle des mutations conductrices pour r\u00e9v\u00e9ler des vuln\u00e9rabilit\u00e9s jusqu\u2019ici inexplor\u00e9es, puis identifier les traitements capables de les exploiter afin d\u2019\u00e9liminer les cellules canc\u00e9reuses.<\/p>\n<p>As outlined in the paper, the approach employs driver-focused CRISPR screens with and without drug in a pool of isogenically controlled cell lines, using next-generation sequencing (NGS) to identify genes that cause cells to \u2018drop out\u2019 of the pool when mutated and treated with a particular drug. Proof-of-concept experiments using PARP (poly-ADP-ribose polymerase) inhibitors\u2014the only drug class currently directed at cancers with LoF mutations\u2014allowed the team to technically optimize their pharmacogenetic approach. They then applied the platform to approved cancer drugs for which real-world data was available and showed that platform-discovered genetic sensitizers impacted patient survival.<\/p>\n<p>\u00ab Ce fut un moment d\u00e9terminant pour moi \u00bb, d\u00e9clare Tomas Babak, Ph. D., directeur scientifique de Leapfrog Bio et auteur correspondant. \u00ab Non seulement nous avons observ\u00e9 une validation \u00e0 100 % dans des mod\u00e8les de x\u00e9nogreffes murines, mais notre plateforme a \u00e9galement permis d\u2019identifier quels patients \u00e9taient les plus susceptibles de r\u00e9pondre \u00e0 des traitements sp\u00e9cifiques en fonction des facteurs g\u00e9n\u00e9tiques \u00e0 l\u2019origine de leurs tumeurs.\n\nContrairement aux approches traditionnelles de l\u00e9talit\u00e9 synth\u00e9tique, fond\u00e9es sur des combinaisons d\u2019invalidations g\u00e9n\u00e9tiques, les interactions pharmacog\u00e9nomiques permettent de capter les effets des m\u00e9dicaments, qui peuvent \u00eatre bien plus complexes qu\u2019une simple invalidation g\u00e9nique. \u00bb <\/p>\n<p>\u00ab Les deux tiers des cancers sont li\u00e9s \u00e0 des mutations avec perte de fonction affectant des g\u00e8nes suppresseurs de tumeurs, o\u00f9 l\u2019absence de prot\u00e9ine fonctionnelle entra\u00eene la croissance tumorale \u00bb, a d\u00e9clar\u00e9 Greg Vontz, chef de la direction de Leapfrog Bio. \u00ab En raison de la difficult\u00e9 \u00e0 d\u00e9velopper des th\u00e9rapies cibl\u00e9es pour des maladies caus\u00e9es par l\u2019absence d\u2019une prot\u00e9ine cible, la majorit\u00e9 des patients atteints de ces cancers n\u2019ont pas acc\u00e8s \u00e0 des traitements g\u00e9n\u00e9tiquement cibl\u00e9s.\n\nNotre plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) r\u00e9pond \u00e0 cet important besoin non satisfait pour les patients et les cliniciens. \u00bb <\/p>\n<p>Mr. Vontz continued, \u201cThere are more than 2,400 clinical-stage cancer therapeutics that have not advanced to FDA approval due to lack of efficacy but were generally safe and well tolerated. After screening only a small portion of these molecules, Leapfrog has identified several compelling opportunities and has filed corresponding intellectual property applications around the discoveries.\u201d<\/p>\n<p><strong>\u00c0 propos de Leapfrog Bio <\/strong><br \/>\nLeapfrog Bio est une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique qui acc\u00e9l\u00e8re le d\u00e9veloppement de m\u00e9dicaments contre le cancer en identifiant des mol\u00e9cules d\u00e9j\u00e0 en phase clinique pouvant \u00eatre repositionn\u00e9es comme th\u00e9rapies cibl\u00e9es pour des cancers associ\u00e9s \u00e0 des mutations conductrices difficiles \u00e0 cibler.\n\nSon principal programme consiste en un essai de preuve de concept de phase 2 \u00e9valuant une petite mol\u00e9cule dans trois cancers solides pr\u00e9sentant une mutation g\u00e9n\u00e9tique avec perte de fonction fr\u00e9quente, pour laquelle il n\u2019existe actuellement aucune option th\u00e9rapeutique cibl\u00e9e.\n\nLa plateforme de pharmacog\u00e9nomique de pr\u00e9cision (PGx) de Leapfrog Bio constitue un syst\u00e8me in vitro reproductible et \u00e9volutif permettant d\u2019identifier des m\u00e9dicaments \u00e0 petites mol\u00e9cules existants pouvant \u00eatre d\u00e9velopp\u00e9s pour traiter des cancers li\u00e9s \u00e0 des mutations avec perte de fonction, avec une forte probabilit\u00e9 de succ\u00e8s clinique.\n\nCette plateforme, valid\u00e9e en clinique, est d\u00e9crite dans l\u2019article \u00e9valu\u00e9 par des pairs intitul\u00e9 \u00ab Pharmacogenomic Discovery of Genetically Targeted Cancer Therapies Optimized Against Clinical Outcomes \u00bb, publi\u00e9 dans la revue npj Precision Oncology (Nature Portfolio). Pour en savoir plus, visitez <a href=\"http:\/\/www.leapfrog.bio\/fr\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"color: rgb(133, 175, 189);\"><u>www.leapfrog.bio<\/u><\/span><\/a>.<\/p>\n<p><strong>Relations avec les m\u00e9dias : <\/strong><br \/>\nJanine McCargo<br \/>\n6 Degrees<br \/>\n(646) 528-4034<br \/>\n<a href=\"mailto:jmccargo@6degreespr.com\">jmccargo@6degreespr.com<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-257","post","type-post","status-publish","format-standard","hentry","category-press_releases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PGx Platform Validated in npj Precision Oncology<\/title>\n<meta name=\"description\" content=\"Leapfrog Bio\u2019s Precision PGx Platform, published in npj Precision Oncology, finds drug\u2013genotype matches for cancers driven by loss-of-function mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PGx Platform Validated in npj Precision Oncology\" \/>\n<meta property=\"og:description\" content=\"Leapfrog Bio\u2019s Precision PGx Platform, published in npj Precision Oncology, finds drug\u2013genotype matches for cancers driven by loss-of-function mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Leapfrog Bio\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-05T07:01:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-19T19:20:48+00:00\" \/>\n<meta name=\"author\" content=\"leapfrogbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"leapfrogbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\"},\"author\":{\"name\":\"leapfrogbio\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\"},\"headline\":\"Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform\u2122\",\"datePublished\":\"2024-09-05T07:01:47+00:00\",\"dateModified\":\"2026-10-19T19:20:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\"},\"wordCount\":752,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\",\"url\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\",\"name\":\"PGx Platform Validated in npj Precision Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#website\"},\"datePublished\":\"2024-09-05T07:01:47+00:00\",\"dateModified\":\"2026-10-19T19:20:48+00:00\",\"description\":\"Leapfrog Bio\u2019s Precision PGx Platform, published in npj Precision Oncology, finds drug\u2013genotype matches for cancers driven by loss-of-function mutations.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.leapfrog.bio\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.leapfrog.bio\/#website\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"name\":\"Leapfrog Bio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.leapfrog.bio\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\",\"name\":\"Leapfrog Bio\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"contentUrl\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"width\":510,\"height\":90,\"caption\":\"Leapfrog Bio\"},\"image\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\",\"name\":\"leapfrogbio\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"caption\":\"leapfrogbio\"},\"sameAs\":[\"https:\/\/www.leapfrog.bio\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PGx Platform Validated in npj Precision Oncology","description":"Leapfrog Bio\u2019s Precision PGx Platform, published in npj Precision Oncology, finds drug\u2013genotype matches for cancers driven by loss-of-function mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/","og_locale":"fr_CA","og_type":"article","og_title":"PGx Platform Validated in npj Precision Oncology","og_description":"Leapfrog Bio\u2019s Precision PGx Platform, published in npj Precision Oncology, finds drug\u2013genotype matches for cancers driven by loss-of-function mutations.","og_url":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/","og_site_name":"Leapfrog Bio","article_published_time":"2024-09-05T07:01:47+00:00","article_modified_time":"2026-10-19T19:20:48+00:00","author":"leapfrogbio","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"leapfrogbio","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#article","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/"},"author":{"name":"leapfrogbio","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3"},"headline":"Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform\u2122","datePublished":"2024-09-05T07:01:47+00:00","dateModified":"2026-10-19T19:20:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/"},"wordCount":752,"commentCount":0,"publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"articleSection":["Press Releases"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/","url":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/","name":"PGx Platform Validated in npj Precision Oncology","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/#website"},"datePublished":"2024-09-05T07:01:47+00:00","dateModified":"2026-10-19T19:20:48+00:00","description":"Leapfrog Bio\u2019s Precision PGx Platform, published in npj Precision Oncology, finds drug\u2013genotype matches for cancers driven by loss-of-function mutations.","breadcrumb":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-announces-publication-in-nature-pj-precision-oncology-validating-its-proprietary-precision-pgx-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.leapfrog.bio\/"},{"@type":"ListItem","position":2,"name":"Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.leapfrog.bio\/#website","url":"https:\/\/www.leapfrog.bio\/","name":"Leapfrog Bio","description":"","publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.leapfrog.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.leapfrog.bio\/#organization","name":"Leapfrog Bio","url":"https:\/\/www.leapfrog.bio\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/","url":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","contentUrl":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","width":510,"height":90,"caption":"Leapfrog Bio"},"image":{"@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3","name":"leapfrogbio","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","caption":"leapfrogbio"},"sameAs":["https:\/\/www.leapfrog.bio"]}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"leapfrogbio","author_link":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"},"_links":{"self":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/comments?post=257"}],"version-history":[{"count":7,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/257\/revisions"}],"predecessor-version":[{"id":686,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/257\/revisions\/686"}],"wp:attachment":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/media?parent=257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/categories?post=257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/tags?post=257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}